AVIR - CIK 0001593899
The table below shows Atea Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$46.39M | -$30.56M | -$39.87M | -$29.85M | -$59.01M | -$16.84M |
| Capital expenditure | - | - | - | - | $44.00K | - |
| Investing cash flow | $29.74M | $85.61M | $56.80M | $24.48M | -$44.00K | - |
| Dividends paid | - | - | - | - | - |
Atea Pharmaceuticals, Inc. reported operating cash flow of -$132.03M for fiscal year 2025. That is up 2.6% from -$135.50M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$7.91M (FY 2018) to -$132.03M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $257.00K | -$347.00K | $150.00K | $165.00K | $223.00K | $471.00K |